N-cadherin is differentially expressed in histological subtypes of papillary renal cell carcinoma

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Ludwig, Behnes Carl ^a   Bernhard, Hemmerlein ^a   Arne, Strauss ^a   Heinz Joachim, Radzun ^a   Felix, Bremmer ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Histological subtypes; Immunohistochemistry; N cadherin; Papillary renal cell carcinoma (RCC)

Indexed keywords

CADHERIN; CDH1 PROTEIN, HUMAN; CDH2 PROTEIN, HUMAN; CDH3 PROTEIN, HUMAN; K CADHERIN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; CELL MEMBRANE; CHEMISTRY; CLASSIFICATION; CYTOPLASM; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; PATHOLOGY; PROGNOSIS;

AGED; ANTIGENS, CD; CADHERINS; CARCINOMA, RENAL CELL; CELL MEMBRANE; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84872172895     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-95     Document Type: Article

References (41)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781. 10.1016/j.ejca.2009.12.014, 20116997.
2. Mydlo JH, Bard RH. Analysis of papillary renal adenocarcinoma. Urology 1987, 30:529-534. 10.1016/0090-4295(87)90430-4, 3686768.
3. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 1997, 10:537-544.
4. Jiang F, Richter J, Schraml P, Bubendorf L, Gasser T, Sauter G, Mihatsch MJ, Moch H. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol 1998, 153:1467-1473. 10.1016/S0002-9440(10)65734-3, 1853413, 9811338.
5. Sanders ME, Mick R, Tomaszewski JE, Barr FG. Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma. Am J Pathol 2002, 161:997-1005. 10.1016/S0002-9440(10)64260-5, 1867241, 12213728.
6. Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, Shuch B, Zisman A, Kabbinavar FF, Belldegrun AS. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 2009, 15:1162-1169.
7. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 2001, 32:590-595. 10.1053/hupa.2001.24984, 11431713.
8. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000, 89:604-614. 10.1002/1097-0142(20000801)89:3<604::AID-CNCR16>3.0.CO;2-Q, 10931460.
9. Pignot G, Elie C, Conquy S, Vieillefond A, Flam T, Zerbib M, Debre B, Amsellem-Ouazana D. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 2007, 69:230-235. 10.1016/j.urology.2006.09.052, 17275070.
10. Angst BD, Marcozzi C, Magee AI. The cadherin superfamily: diversity in form and function. Journal of cell science 2001, 114:629-641.
11. Potter E, Bergwitz C, Brabant G. The cadherin-catenin system: implications for growth and differentiation of endocrine tissues. Endocr Rev 1999, 20:207-239. 10.1210/er.20.2.207, 10204118.
12. Stemmler MP. Cadherins in development and cancer. Mol Biosyst 2008, 4:835-850. 10.1039/b719215k, 18633485.
13. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen-Dale AL. E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 1998, 185:262-266. 10.1002/(SICI)1096-9896(199807)185:3<262::AID-PATH97>3.0.CO;2-Y, 9771479.
14. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. The Journal of cell biology 2000, 148:779-790. 10.1083/jcb.148.4.779, 2169367, 10684258.
15. Eble JN. International Agency for Research on Cancer: Pathology and genetics of tumours of the urinary system and male genital organs 2004, IARC-Press, Lyon.
16. Leroy X, Zini L, Leteurtre E, Zerimech F, Porchet N, Aubert JP, Gosselin B, Copin MC. Morphologic subtyping of papillary renal cell carcinoma: correlation with prognosis and differential expression of MUC1 between the two subtypes. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2002, 15:1126-1130.
17. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Archives of pathology & laboratory medicine 2011, 135:92-109.
18. Skinnider BF, Folpe AL, Hennigar RA, Lim SD, Cohen C, Tamboli P, Young A, de Peralta-Venturina M, Amin MB. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol 2005, 29:747-754. 10.1097/01.pas.0000163362.78475.63, 15897741.
19. Perret AG, Clemencon A, Li G, Tostain J, Peoc'h M. Differential expression of prognostic markers in histological subtypes of papillary renal cell carcinoma. BJU Int 2008, 102:183-187. 10.1111/j.1464-410X.2008.07605.x, 18422770.
20. Zhou M, Roma A, Magi-Galluzzi C. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. Clinics in laboratory medicine 2005, 25:247-257. 10.1016/j.cll.2005.01.004, 15848735.
21. Avery AK, Beckstead J, Renshaw AA, Corless CL. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 2000, 24:203-210. 10.1097/00000478-200002000-00006, 10680888.
22. Medeiros LJ, Michie SA, Johnson DE, Warnke RA, Weiss LM. An immunoperoxidase study of renal cell carcinomas: correlation with nuclear grade, cell type, and histologic pattern. Hum Pathol 1988, 19:980-987. 10.1016/S0046-8177(88)80016-9, 2456980.
23. Biddlestone LR, Fleming S. Morphological evidence that A-CAM is a major intercellular adhesion molecule in human kidney. J Pathol 1991, 164:9-15. 10.1002/path.1711640103, 2056393.
24. Biddlestone LR, Fleming S. Calcium dependence of A-CAM function in human renal epithelium. J Pathol 1992, 166:163-169. 10.1002/path.1711660213, 1560317.
25. Markovic-Lipkovski J, Brasanac D, Muller GA, Muller CA. Cadherins and integrins in renal cell carcinoma: an immunohistochemical study. Tumori 2001, 87:173-178.
26. Leckband D, Prakasam A. Mechanism and dynamics of cadherin adhesion. Annu Rev Biomed Eng 2006, 8:259-287. 10.1146/annurev.bioeng.8.061505.095753, 16834557.
27. Hatta K, Takagi S, Fujisawa H, Takeichi M. Spatial and temporal expression pattern of N-cadherin cell adhesion molecules correlated with morphogenetic processes of chicken embryos. Dev Biol 1987, 120:215-227. 10.1016/0012-1606(87)90119-9, 3817290.
28. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Investig 2009, 119:1417-1419. 10.1172/JCI39675, 2689122, 19487817.
29. Harada KI, Miyake H, Kusuda Y, Fujisawa M. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy. BJU Int 2012,
30. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. The Journal of cell biology 1999, 147:631-644. 10.1083/jcb.147.3.631, 2151177, 10545506.
31. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9:265-273. 10.1038/nrc2620, 19262571.
32. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005, 65:9455-9462. 10.1158/0008-5472.CAN-05-1058, 16230409.
33. Han AC, Soler AP, Knudsen KA, Salazar H. Distinct cadherin profiles in special variant carcinomas and other tumors of the breast. Hum Pathol 1999, 30:1035-1039. 10.1016/S0046-8177(99)90220-4, 10492037.
34. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. Journal of cell science 2008, 121:727-735. 10.1242/jcs.000455, 18322269.
35. Yamauchi M, Yoshino I, Yamaguchi R, Shimamura T, Nagasaki M, Imoto S, Niida A, Koizumi F, Kohno T, Yokota J, et al. N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells. American journal of cancer research 2011, 1:823-833. 3196281, 22016830.
36. Wong AS, Maines-Bandiera SL, Rosen B, Wheelock MJ, Johnson KR, Leung PC, Roskelley CD, Auersperg N. Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: influence of family history of ovarian cancer. International journal of cancer Journal international du cancer 1999, 81:180-188.
37. Horstmann M, Geiger LM, Vogel U, Schmid H, Hennenlotter J, Kuehs U, Merseburger AS, Kruck S, Stenzl A, Bedke J. Kidney-specific cadherin correlates with the ontogenetic origin of renal cell carcinoma subtypes: an indicator of a malignant potential?. World journal of urology 2011, 30(4):525-531.
38. Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD. Cadherin switching in ovarian cancer progression. International journal of cancer Journal international du cancer 2003, 106:172-177.
39. Chartier NT, Oddou CI, Laine MG, Ducarouge B, Marie CA, Block MR, Jacquier-Sarlin MR. Cyclin-dependent kinase 2/cyclin E complex is involved in p120 catenin (p120ctn)-dependent cell growth control: a new role for p120ctn in cancer. Cancer Res 2007, 67:9781-9790. 10.1158/0008-5472.CAN-07-0233, 2695941, 17942908.
40. Cheung LW, Leung PC, Wong AS. Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer. Oncogene 2010, 29:2427-2440. 10.1038/onc.2009.523, 20118984.
41. Mariotti A, Perotti A, Sessa C, Ruegg C. N-cadherin as a therapeutic target in cancer. Expert opinion on investigational drugs 2007, 16:451-465. 10.1517/13543784.16.4.451, 17371194.